SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...

B ERLIN -- The antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) delivered impressive results in ...

High TILs may predict which patients with early HER2-positive breast cancer may have a reduced risk for disease relapse or death with Herceptin treatment. High tumor infiltrating lymphocytes (TILs) in ...

– At three years, 88.3 percent of people treated with Kadcyla in the adjuvant HER2-positive early breast cancer setting did not have their breast cancer return compared to 77.0 percent treated with ...

SGMC Health now offers in-house HER2 testing for breast cancer, making it the only provider within a 150-mile radius to offer ...

Trastuzumab rezetecan significantly improves progression-free survival in HER2-positive breast cancer, outperforming standard treatments in a pivotal trial.

Local clinical trials at Bakersfield’s Comprehensive Blood and Cancer Center are advancing breast cancer treatments and saving lives through early detection and personalized care.

Shanghai Henlius Biotech’s partner, Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has received permission from the Food and Drug Administration for Hercessi (HLX02, ...

Teva Pharmaceuticals International said Monday that Prestige received marketing authorization last year from the European Commission for Tuznue, a biosimilar to Herceptin approved for the treatment of ...

Tuznue ® is approved for the treatment of breast cancer and metastatic gastric cancer. Prestige Biopharma received the European Commission (EC) marketing authorization for Tuznue ® in September 2024.

Sept. 1, 2005 — The U.S. Food and Drug Administration (FDA) and Genentech, Inc., have warned healthcare professionals via letter of study data linking trastuzumab (Herceptin) therapy to a ...